Nifty
Sensex
:
:
18534.40
62622.24
-99.45 (-0.53%)
-346.89 (-0.55%)

Pharmaceuticals & Drugs - API

Rating :
55/99

BSE: 532482 | NSE: GRANULES

281.95
31-May-2023
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 281.40
  • 284.40
  • 279.85
  • 281.95
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  785679
  •  2218.41
  •  381.00
  •  226.95

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 6,830.45
  • 13.22
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 7,513.75
  • 0.53%
  • 2.41

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 42.02%
  • 3.72%
  • 21.14%
  • FII
  • DII
  • Others
  • 23.9%
  • 5.03%
  • 4.19%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.29
  • 17.45
  • 13.15

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 23.85
  • 20.98
  • 6.56

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 28.91
  • 28.77
  • 10.02

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.31
  • 15.49
  • 16.58

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.24
  • 2.85
  • 3.49

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.70
  • 10.32
  • 10.95

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Var%
Dec 22
Dec 21
Var%
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Net Sales
1,195.50
1,029.97
16.07%
1,146.13
996.77
14.98%
1,150.73
888.33
29.54%
1,019.56
849.85
19.97%
Expenses
967.38
837.28
15.54%
914.83
823.04
11.15%
907.83
737.15
23.15%
808.05
648.42
24.62%
EBITDA
228.12
192.70
18.38%
231.29
173.73
33.13%
242.91
151.18
60.68%
211.50
201.43
5.00%
EBIDTM
19.08%
18.71%
20.18%
17.43%
21.11%
17.02%
20.74%
23.70%
Other Income
3.38
3.96
-14.65%
0.95
4.87
-80.49%
4.79
4.35
10.11%
4.67
7.62
-38.71%
Interest
18.80
6.36
195.60%
16.97
4.59
269.72%
13.22
5.46
142.12%
6.94
6.79
2.21%
Depreciation
48.71
40.18
21.23%
48.36
39.23
23.27%
44.06
39.84
10.59%
43.36
39.38
10.11%
PBT
163.99
150.12
9.24%
166.90
134.78
23.83%
190.41
110.23
72.74%
165.87
162.87
1.84%
Tax
44.38
39.12
13.45%
42.57
33.90
25.58%
45.32
29.55
53.37%
38.30
42.67
-10.24%
PAT
119.60
111.00
7.75%
124.33
100.88
23.25%
145.09
80.68
79.83%
127.57
120.20
6.13%
PATM
10.00%
10.78%
10.85%
10.12%
12.61%
9.08%
12.51%
14.14%
EPS
4.94
4.48
10.27%
5.14
4.07
26.29%
5.84
3.26
79.14%
5.14
4.85
5.98%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
4,511.92
3,764.92
3,237.54
2,598.65
2,279.20
1,684.62
1,410.57
1,357.18
1,292.92
1,095.86
764.37
Net Sales Growth
19.84%
16.29%
24.59%
14.02%
35.29%
19.43%
3.93%
4.97%
17.98%
43.37%
 
Cost Of Goods Sold
2,307.29
1,883.64
1,391.28
1,280.93
1,255.56
896.32
679.63
725.03
746.95
645.25
466.92
Gross Profit
2,204.63
1,881.28
1,846.27
1,317.72
1,023.64
788.30
730.93
632.15
545.97
450.61
297.45
GP Margin
48.86%
49.97%
57.03%
50.71%
44.91%
46.79%
51.82%
46.58%
42.23%
41.12%
38.91%
Total Expenditure
3,598.09
3,043.30
2,382.31
2,073.33
1,895.16
1,406.20
1,111.73
1,081.29
1,084.31
937.57
679.35
Power & Fuel Cost
-
74.66
68.85
59.74
57.67
48.22
38.67
34.97
45.73
36.70
37.71
% Of Sales
-
1.98%
2.13%
2.30%
2.53%
2.86%
2.74%
2.58%
3.54%
3.35%
4.93%
Employee Cost
-
366.44
324.29
259.04
209.82
165.21
140.19
117.57
106.96
85.84
59.71
% Of Sales
-
9.73%
10.02%
9.97%
9.21%
9.81%
9.94%
8.66%
8.27%
7.83%
7.81%
Manufacturing Exp.
-
298.74
228.39
177.94
157.62
120.84
88.60
66.97
50.89
38.68
24.34
% Of Sales
-
7.93%
7.05%
6.85%
6.92%
7.17%
6.28%
4.93%
3.94%
3.53%
3.18%
General & Admin Exp.
-
134.41
172.28
125.63
99.96
83.05
67.65
60.38
59.84
44.42
26.96
% Of Sales
-
3.57%
5.32%
4.83%
4.39%
4.93%
4.80%
4.45%
4.63%
4.05%
3.53%
Selling & Distn. Exp.
-
247.45
159.80
112.17
91.84
83.08
81.37
67.75
71.70
85.04
61.70
% Of Sales
-
6.57%
4.94%
4.32%
4.03%
4.93%
5.77%
4.99%
5.55%
7.76%
8.07%
Miscellaneous Exp.
-
37.96
37.42
57.88
22.69
9.49
15.61
8.62
2.24
1.64
61.70
% Of Sales
-
1.01%
1.16%
2.23%
1.00%
0.56%
1.11%
0.64%
0.17%
0.15%
0.26%
EBITDA
913.82
721.62
855.23
525.32
384.04
278.42
298.84
275.89
208.61
158.29
85.02
EBITDA Margin
20.25%
19.17%
26.42%
20.22%
16.85%
16.53%
21.19%
20.33%
16.13%
14.44%
11.12%
Other Income
13.79
18.22
26.88
36.56
26.68
10.84
9.93
5.62
4.34
4.31
2.06
Interest
55.93
23.21
26.28
27.02
28.46
33.06
32.26
37.07
32.35
20.43
17.67
Depreciation
184.49
158.63
151.46
136.95
105.48
76.20
71.51
58.40
52.65
29.81
23.08
PBT
687.17
558.00
704.36
397.90
276.78
180.00
204.99
186.03
127.96
112.36
46.32
Tax
170.57
145.24
154.91
115.73
89.11
63.40
65.20
61.15
37.05
37.13
13.76
Tax Rate
24.82%
26.03%
21.99%
27.19%
32.20%
35.22%
31.81%
32.87%
28.95%
33.05%
29.71%
PAT
516.59
412.76
549.46
309.91
187.67
116.60
139.79
124.89
90.91
75.23
32.57
PAT before Minority Interest
516.59
412.76
549.46
309.91
187.67
116.60
139.79
124.89
90.91
75.23
32.57
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
11.45%
10.96%
16.97%
11.93%
8.23%
6.92%
9.91%
9.20%
7.03%
6.86%
4.26%
PAT Growth
25.16%
-24.88%
77.30%
65.14%
60.95%
-16.59%
11.93%
37.38%
20.84%
130.98%
 
EPS
21.35
17.06
22.70
12.81
7.75
4.82
5.78
5.16
3.76
3.11
1.35

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
2,586.53
2,173.27
1,843.72
1,529.47
1,304.18
903.60
661.60
431.16
355.96
274.85
Share Capital
24.80
24.77
25.42
25.42
25.38
22.87
21.67
20.43
20.28
20.13
Total Reserves
2,545.01
2,126.23
1,800.02
1,493.09
1,273.38
878.28
611.13
410.74
335.43
254.41
Non-Current Liabilities
282.83
366.30
485.98
552.63
488.19
187.99
246.62
356.52
343.51
202.00
Secured Loans
233.70
333.81
414.83
478.78
433.13
123.90
183.66
302.59
295.86
174.85
Unsecured Loans
0.00
0.00
6.69
0.00
0.00
0.34
0.55
0.62
13.38
0.65
Long Term Provisions
28.31
24.84
21.50
12.58
7.70
7.25
5.58
4.03
3.97
2.04
Current Liabilities
1,641.60
1,173.10
893.40
896.48
877.91
787.13
654.75
415.03
292.54
205.78
Trade Payables
638.61
541.05
356.88
323.48
274.35
215.98
181.10
187.63
135.54
91.84
Other Current Liabilities
200.85
194.25
153.16
113.60
69.84
93.43
79.21
88.98
47.78
23.77
Short Term Borrowings
765.58
409.27
371.69
454.21
525.10
473.83
392.85
124.97
100.91
85.46
Short Term Provisions
36.56
28.53
11.66
5.20
8.62
3.90
1.58
13.45
8.30
4.71
Total Liabilities
4,511.52
3,712.67
3,223.10
2,978.58
2,670.28
1,878.72
1,562.97
1,202.71
992.01
682.63
Net Block
1,541.17
1,332.00
1,203.97
944.25
776.73
644.34
559.94
616.55
482.47
263.46
Gross Block
2,461.76
2,145.15
1,875.23
1,472.94
1,199.63
983.66
822.98
843.76
653.90
387.41
Accumulated Depreciation
920.59
813.15
671.26
528.69
422.90
339.32
263.05
227.21
171.43
123.95
Non Current Assets
2,006.54
1,715.68
1,594.41
1,696.34
1,483.71
1,050.55
744.97
699.69
611.55
388.87
Capital Work in Progress
356.23
239.08
294.20
495.95
514.52
267.43
76.56
62.03
124.56
108.80
Non Current Investment
19.67
18.99
19.34
210.42
156.56
108.23
70.11
0.19
0.19
0.19
Long Term Loans & Adv.
89.47
125.61
76.89
45.72
35.91
30.56
38.37
20.76
4.33
16.42
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.15
0.00
0.00
Current Assets
2,504.98
1,997.00
1,628.70
1,282.24
1,186.57
828.16
818.00
500.36
376.92
288.88
Current Investments
0.00
0.00
109.85
0.00
0.00
0.00
0.00
0.00
0.00
9.46
Inventories
978.55
782.18
438.43
384.21
279.95
269.18
253.72
224.52
174.16
136.48
Sundry Debtors
924.95
765.42
662.04
673.54
628.25
417.70
375.35
136.91
110.91
71.02
Cash & Bank
409.46
271.04
283.94
89.04
115.64
49.80
130.29
65.31
41.75
41.71
Other Current Assets
192.02
50.74
42.60
36.99
162.73
91.49
58.65
73.63
50.10
30.21
Short Term Loans & Adv.
130.35
127.61
91.83
98.46
114.09
51.66
48.68
2.05
28.76
16.93
Net Current Assets
863.38
823.90
735.30
385.76
308.65
41.03
163.25
85.33
84.38
83.09
Total Assets
4,511.52
3,712.68
3,223.11
2,978.58
2,670.28
1,878.71
1,562.97
1,202.72
992.01
682.64

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
332.05
432.48
476.19
262.24
-0.65
188.24
151.43
150.28
107.95
91.18
PBT
558.00
704.36
425.64
276.78
180.00
204.99
186.03
127.96
112.36
46.32
Adjustment
176.29
194.43
156.88
149.85
107.45
95.14
92.63
85.37
50.39
41.46
Changes in Working Capital
-257.19
-274.95
12.75
-75.94
-230.03
-52.37
-79.70
-31.34
-31.03
14.60
Cash after chg. in Working capital
477.10
623.84
595.27
350.69
57.42
247.77
198.97
182.00
131.73
102.39
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-145.05
-191.37
-119.08
-88.45
-58.07
-59.53
-47.54
-31.72
-23.78
-11.20
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-380.11
-277.13
-160.63
-269.82
-462.31
-326.09
-161.65
-145.55
-254.63
-127.79
Net Fixed Assets
-302.61
-204.42
-124.57
-176.36
-282.01
-249.86
-75.62
-231.53
-64.60
-89.18
Net Investments
-5.00
-36.29
-48.78
-431.34
-0.01
13.84
-16.48
72.98
-94.69
-17.96
Others
-72.50
-36.42
12.72
337.88
-180.29
-90.07
-69.55
13.00
-95.34
-20.65
Cash from Financing Activity
190.00
-299.31
-212.85
-17.43
528.62
55.87
85.67
18.83
146.72
46.33
Net Cash Inflow / Outflow
141.94
-143.97
102.70
-25.01
65.66
-81.98
75.44
23.56
0.04
9.72
Opening Cash & Equivalents
41.84
185.93
83.02
108.03
42.37
124.35
54.85
41.75
41.71
31.98
Closing Cash & Equivalent
184.71
41.84
185.93
83.02
108.03
42.37
130.29
65.31
41.75
41.71

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
103.62
86.85
71.80
59.73
51.17
39.40
29.20
20.98
17.36
13.40
ROA
10.04%
15.84%
9.99%
6.64%
5.13%
8.12%
9.03%
8.31%
8.98%
5.19%
ROE
17.49%
27.64%
18.54%
13.32%
10.60%
18.23%
23.53%
23.29%
24.20%
12.67%
ROCE
17.37%
25.42%
17.22%
12.71%
11.09%
16.57%
20.16%
18.75%
19.90%
12.95%
Fixed Asset Turnover
2.26
1.97
1.75
1.78
1.55
1.59
1.66
1.77
2.14
2.11
Receivable days
59.15
65.94
83.34
100.03
112.83
100.84
67.60
33.47
29.73
38.66
Inventory Days
61.61
56.39
51.34
51.03
59.23
66.49
63.11
54.79
50.77
57.37
Payable days
114.29
117.79
58.20
54.96
62.37
64.87
59.99
53.57
43.67
44.19
Cash Conversion Cycle
6.46
4.54
76.48
96.10
109.70
102.46
70.72
34.69
36.83
51.84
Total Debt/Equity
0.43
0.39
0.49
0.65
0.75
0.73
1.01
1.14
1.25
1.00
Interest Cover
25.04
27.80
16.75
10.72
6.44
7.36
6.02
4.96
6.50
3.62

News Update:


  • Granules India gets USFDA’s approval for Venlafaxine Hydrochloride Capsules
    19th May 2023, 09:06 AM

    It is bioequivalent to the reference listed drug product, Effexor XR Extended-Release Capsules of Upjohn US 2 LLC

    Read More
  • Granules India launches packaging facility in US
    29th Mar 2023, 11:46 AM

    The facility recently received USFDA approval with zero 483 observations

    Read More
  • Granules India gets USFDA’s nod for Gabapentin Tablets
    29th Mar 2023, 09:24 AM

    The current annual U.S. market for Gabapentin Tablets is approximately $145 million

    Read More
  • USFDA concludes audit at Granules' arm facility with zero observations
    21st Mar 2023, 15:12 PM

    The facility was inspected by the US FDA from March 15, 2023 to March 20, 2023

    Read More
  • Granules India receives USFDA’s approval for Losartan Potassium Tablets
    27th Feb 2023, 09:22 AM

    Granules now has a total of 54 ANDA approvals from USFDA

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.